SYS6026
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 17, 2026
A Multicenter, Open-Label, Phase I Clinical Study Evaluating the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of SYS6026 as Monotherapy or in Combination for Advanced Solid Tumors
(SGO 2026)
- No abstract available
Clinical • Metastases • Monotherapy • P1 data • PK/PD data • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1